This week's StoxEurope deep-dive takes UCB SA/NV (UCB, Euronext Brussels) — a Belgian biopharmaceutical — through the triangulation method. It is the first deep-dive in the series where the selection rules leave a single intrinsic model standing.
The two models that switched off did so for opposite reasons. UCB pays out 17,7 % of basic earnings, far below the 40 % at which a dividend stream can carry a valuation, so the
dividend discount model is out. And at roughly 3,9× book value, above the 3× line, the residual income model is out too — UCB's value sits in intellectual property and pipeline, not on the balance sheet. That leaves the discounted cash flow alone, and it changes what this article can claim.
One of three intrinsic models applies, so there is no Confluence Zone — zone reporting is suspended under the interim methodology rules, and with one model none could form in any case. No consolidated fair value is offered.
What the model reads
Model | Point estimate | Sensitivity range |
|---|---|---|
DCF | €206,24 | €154,80–€310,76 |
Market Cross-Check (Sanofi, Novartis, AstraZeneca): EV/EBITDA €181,32 · Relative €180,77 — load-bearing here, reported beside the DCF, never folded into it.
The price is €221,30 (as at 30 July 2026), above the DCF estimate and above both peer readings, but well inside the sensitivity range.
Two numbers worth stating plainly: 77 % of the DCF's value sits in the terminal value, and the WACC-minus-growth spread is 5,84 %. A model with three-quarters of its answer beyond year five is a model whose long-run assumptions are doing the work.
The one caveat
[OPERATOR — draft, approve or replace] A discounted cash flow built on marketed medicines systematically under-prices a company whose value lies partly in what it has not yet launched: probabilities of clinical and regulatory success are not figures any public source provides. UCB spent €2,33 bn on pipeline this year; this estimate charges the balance sheet for it — some €14,80 per share — and counts none of the return.
That is the largest single thing standing between this number and the market's, and it is precisely what no published source can yet price.
The full workings
Read the full valuation — every assumption, every model, the full
workings: https://stoxeurope.com/valuation/ucb/
Analysis dated 30 July 2026.
Disclosures
The author holds a position in UCB SA/NV as at 20 July 2026.
This valuation is a StoxEurope opinion, based on honest research. Mistakes are possible.
This article demonstrates a valuation methodology. It is not an investment recommendation, is not personalised to any reader's circumstances, and every figure in it depends entirely on the stated assumptions. Do your own research.